Work

Children's Oncology Group's 2013 blueprint for research: Non‐Hodgkin lymphoma

Year: 2012

Type: review

Abstract: Non-Hodgkin lymphomas account for approximately 7% of cancers diagnosed in patients less than 20 years of age, with approximately 800 cases diagnosed annually at COG institutions. With current therapies, cure rates range from 70% to over 90%, even for children with disseminated disease. However, two major challenges need to be overcome: (i) to optimize upfront treatment to prevent relapse since prognosis for patients with relapsed disease remains poor and (ii) minimize long-term side effects in survivors. Hence, the future initiatives for the treatment of pediatric NHL are to utilize novel targeted therapies to not only improve outcomes but to decrease bystander organ toxicities and late effects.

Source: Pediatric Blood & Cancer

DOI: 10.1002/pbc.24416

Authors: Catherine M. Bollard, Megan S. Lim, Thomas G. Gross

Institutions: Baylor College of Medicine, Texas Children's Hospital, University of Michigan, Nationwide Children's Hospital

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute